Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.50 | -3.08% | 15.75 | 15.50 | 16.00 | 16.25 | 15.75 | 16.25 | 326,625 | 10:34:41 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0125 | -13.00 | 36.74M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 08/11/2024 15:55 | Show you some data from elsewhere , on the weekend for sbtx Not show it in live market Wouldnt be fair | putinaire | |
| 08/11/2024 15:53 | 'tradition' Key issue Suddenly another 5 billion competitors | putinaire | |
| 08/11/2024 15:48 | Great factoring numbers Why does it stop at gross imaginary profit? | putinaire | |
| 08/11/2024 15:47 | There is a psoriasis society i found, describing the effectiveness of the product. They said they may as well have drank water. One even claimed bad side affects. However, to see it, you first have to filter out allthe shareholders here...whom seemingly all developed psoriasis at the same time....and chatted at the P Society, at the same time...and found the miracle product...at the same time... | putinaire | |
| 08/11/2024 15:33 | Not sure I agree…psoriasi Why are these sufferers not buying the product or at least trying it, where 80% of users see a massive improvement and buy it after trying it. I am not saying everyone with psoriasis will buy it but 800 ish customer after 4 years? Feels like the company is leaving this product behind now and moving away from skin microbiome to more tradition Dermatonics product offerings. | theterrier | |
| 08/11/2024 13:13 | 400k sales isn’t bad if you factor in the customer | kreature | |
| 08/11/2024 09:06 | AxisBiotix Sales (YE) 2021 Launch Q4 2022 Retail sales £74,761. Gross Profit £45,337. Subscribers est 130. 2023 Retail sales £132,057. Gross Profit £87,077. Subscribers est 227. Growth YoY 77% 2024 Retail sales £248,000. Gross Profit £155,746. Subscribers est 525. Growth YoY 88% E2025 Retail sales £396,800. Gross Profit £249,194. Subscribers est 840. Growth YoY 60% Sold in USA, UK, EU Spain, Italy, France. DYOR. Went back over the last YE recent IM. Axis sales growth expectations are disappointing to me given the size of the market and how good the product is/claims/WP deal/ massive EU market expansion/dedicated sales/marketing team. Securing around 400 new customers in 23-24 seems to be the target set, 60% rise but surely board is setting more stretching targets than this given the base. Why is the growth slowing given WP are on board, its sold on amazon etc Is the product is being shelved. Would surely expect growth in YoY % not a decrease- Mention of NPF accreditation in USA to help sales but no timelines and talk of price point needing adjusting. Hard to believe that the company is targeting only sales of £400K- 4y after launch. I am missing the strategy here? | theterrier | |
| 07/11/2024 19:48 | Oh dear …bit a contrast in music taste | kreature | |
| 07/11/2024 15:34 | pinggggggggggggggggg | the ploppolator |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
